Fate Therapeutics, Inc. (FATE)

Market Cap	262.41M +63.7%
Revenue (ttm)	6.49M -23.4%
Net Income	-126.00M
EPS	-1.05
Shares Out	119.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	393,963
Open	2.130
Previous Close	2.130
Day's Range	2.100 - 2.275
52-Week Range	0.950 - 3.230
Beta	2.53
Analysts	Buy
Price Target	5.74 (+162.1%)
Est. Earnings	Nov 12, 2026

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2013
• Employees: 161
• Stock Exchange: Nasdaq
• Ticker Symbol: FATE
• Website: https://www.fatetherapeutics.com

Financial Performance

In 2025, Fate Therapeutics's revenue was $6.65 million, a decrease of -51.24% compared to the previous year's $13.63 million. Losses were -$136.32 million, -26.82% less than in 2024.

Analyst Summary

According to 11 analysts, the average rating for FATE stock is "Buy." The 12-month stock price target is $5.74, which is an increase of 162.10% from the latest price.

Price Target

$5.74

(162.10% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 9, 2026

Data Sources Report a data error